These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30152527)

  • 41. First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
    Shisha T; Posch MG; Lehmann J; Feifel R; Junt T; Hawtin S; Schuemann J; Avrameas A; Danekula R; Misiolek P; Siegel R; Gergely P
    Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):553-566. PubMed ID: 37532923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release-activated calcium (CRAC) channel modulator in healthy volunteers.
    Barde PJ; Viswanadha S; Veeraraghavan S; Vakkalanka SV; Nair A
    J Clin Pharm Ther; 2021 Jun; 46(3):677-687. PubMed ID: 33314326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na
    Rothenberg ME; Tagen M; Chang JH; Boyce-Rustay J; Friesenhahn M; Hackos DH; Hains A; Sutherlin D; Ward M; Cho W
    Clin Drug Investig; 2019 Sep; 39(9):873-887. PubMed ID: 31172446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
    Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
    Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.
    Kanodia J; Lo A; Baldwin RM; Colley K; Zhou K; Bourdet DL
    Clin Transl Sci; 2020 Nov; 13(6):1307-1315. PubMed ID: 32506827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S; Boy M; Chow V; Chan G
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders.
    Gehin M; Melchior M; Welford RWD; Sidharta PN; Dingemanse J
    Clin Transl Sci; 2021 Mar; 14(2):558-567. PubMed ID: 33142037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
    Shi JG; Chen X; Lee F; Emm T; Scherle PA; Lo Y; Punwani N; Williams WV; Yeleswaram S
    J Clin Pharmacol; 2014 Dec; 54(12):1354-61. PubMed ID: 24965573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
    Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR
    Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
    Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
    Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313.
    Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110166. PubMed ID: 33159976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.
    Chandorkar G; Zhan Q; Donovan J; Rege S; Patino H
    BMC Pharmacol Toxicol; 2017 Mar; 18(1):24. PubMed ID: 28347318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
    Täubel J; Ferber G; Fernandes S; Lorch U; Santamaría E; Izquierdo I
    PLoS One; 2016; 11(9):e0163020. PubMed ID: 27632557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
    Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
    Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.
    Pfeifer ND; Lo A; Bourdet DL; Colley K; Singh D
    Clin Transl Sci; 2021 Nov; 14(6):2556-2565. PubMed ID: 34318597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
    Hanrahan JP; Wakefield JD; Wilson PJ; Mihova M; Chickering JG; Ruff D; Hall M; Milne GT; Currie MG; Profy AT
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):564-575. PubMed ID: 30422390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
    Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
    Landry I; Nakai K; Ferry J; Aluri J; Hall N; Lalovic B; Moline ML
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):153-165. PubMed ID: 32468649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.